Ignite Creation Date:
2025-12-24 @ 5:29 PM
Ignite Modification Date:
2026-02-22 @ 7:22 PM
Study NCT ID:
NCT04278768
Status:
RECRUITING
Last Update Posted:
2025-08-17
First Post:
2020-02-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Sponsor:
Curis, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Acute Myelogenous Leukemia | View |
| None | Myelodysplastic Syndrome | View |
| None | AML | View |
| None | MDS | View |
| None | Interleukin-1 receptor-associated kinase 4 (IRAK4) | View |
| None | FLT3-ITD or TKD mutant | View |
| None | FLT3 Wild Type (WT) | View |
| None | Relapse/refractory to hypomethylating agent (HMA) | View |
| None | spliceosome mutation | View |
| None | SF3B1 | View |
| None | U2AF1 | View |
| None | Serine/arginine-rich splicing factor 2 (SRSF2) | View |
| None | Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2 … | View |
| None | higher-risk MDS | View |
| None | failing prior treatment | View |
| None | R/R AML or relapse/refractory AML | View |
| None | R/R hrMDS or relapse/refractory hrMDS | View |
| None | FLT3 mutation | View |
| None | FLT3 inhibitor | View |